Skip to main content

Advertisement

SpringerLink
Log in

Safety and efficacy of rituximad to treat systemic lupus erythematosus in children

  • Clinical Trials Report
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Lehman TJA, Onel K: Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. J Pediatr 2000, 136:243–247.

    Article  PubMed  CAS  Google Scholar 

  2. Silverman GJ, Weisman S: Rituximab therapy and autoimmune disorders. Arthritis Rheum 2003, 48:1484–1492.

    Article  PubMed  CAS  Google Scholar 

  3. Adams A, MacDermott EJ, Lehman TJ: Pharmacotherapy of lupus nephritis in children: a recommended treatment approach. Drugs 2006, 66:1191–1207.

    Article  PubMed  CAS  Google Scholar 

  4. Anolik J, Barnard J, Cappione A, et al.: Rituximab improves peripheral B cell abnormalities human systemic lupus erythematosus. Arthritis Rheum 2004, 50:3580–3590.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Emma Jane MacDermott MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas J. A. Lehman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

MacDermott, E.J., Lehman, T.J.A. Safety and efficacy of rituximad to treat systemic lupus erythematosus in children. Curr Rheumatol Rep 8, 440–441 (2006). https://doi.org/10.1007/s11926-006-0039-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-006-0039-x

Keywords

Search

Navigation